Eye Tech Growth Occuity's PM1 is planned as the world's first handheld, non-contacting optical pachymeter, with future expansions into axial length, pupillometry and keratometry for human and veterinary optometry. This platform enables sales to optometry and ophthalmology clinics, hospitals, and device distributors, as well as non-clinical screening in high street opticians, pharmacies and care homes.

Strategic Partnerships Current and past collaborations, including with Boehringer Ingelheim on animal diabetes tech and Innovate UK funding for the AGE reader, indicate a clear path to co-development, licensing and grant-funded programs that can rapidly expand sales channels and markets.

Clinical Training Occuity is developing training materials and best-practice guidance as devices are deployed in large-scale real-world research, enabling a services-led sales approach with clinician onboarding, ongoing support, and training subscriptions to drive adoption and device utilization.

IP Validation A strong IP position with multiple granted patents and industry recognition supports credibility with distributors and healthcare partners, facilitating licensing conversations and faster market entry across international markets.

Screening Market Non-clinical disease screening products for diabetes and Alzheimer's have high potential in opticians, pharmacies and care homes, providing bundled value with eye health devices and aligning with current trends toward accessible, non-invasive screening.